Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631

Septerna, Inc.

2026-Q1 EPS reported -$0.19 revenue$26,523,000

Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.
Cash $522.1M as of March 31, 2026; expected runway into 2029.
SEP-631 Phase 1 positive: well tolerated, supports once-daily dosing; Phase 2b in CSU planned H2 2026.
SEP-479 Phase 1 trial for hypoparathyroidism initiated; data expected late 2026/early 2027.
CMO Jae Kim departing; successor search initiated; will serve advisory role during transition.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Septerna, Inc. reported first quarter ended March 31, 2026 results: revenue $26.5 million, net income $8.6 million.

Period: first quarter ended March 31, 2026
Revenue: $26.5 million
Net income: $8.6 million
Result: reported results

Exact text from the filing

$522.1 million as of March 31, 2026. Septerna expects its existing cash runway to fund operations at least into 2029. o Revenue: Revenue from the Novo Nordisk collaboration was $26.5 million for the quarter ended March 31, 2026, compared to $0.2 million from Vertex for the quarter ended March 31, 2025. Revenue for the quarter ended March 31, 2026 included the

View on SEC.gov

Browse all earnings releases →

Septerna, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216723

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.